



TTD Committee

CHAIR: Jed Gorlin

PURPOSE: To provide consultation, as needed, on all facets of transfusion and cellular therapy related diseases and related laboratory tests. To prepare reports for the membership on developments and issues in these areas, as appropriate.

- CHARGES:**
1. Continue to monitor the status of current and emerging infectious diseases that could be transmitted through transfusion or tissue or cellular transplantation and the potential adverse outcomes for patients, for purposes of defining AABB patient-related transfusion safety strategies. Report to the Board as there are developments.
 2. Monitor development of the tests and screening procedures for infectious diseases and recommend action to the Board for members to follow in response to public concerns. Report on findings. If the report contains recommendations for change in policy, submit simultaneously to the Standards Committee.
 3. Monitor pathogen reduction procedures and their effectiveness. Report to the Board as information is available. Assist in determining the risk-benefit of such procedures per other AABB initiatives.
 4. Develop recommendations for the Board concerning re-entry protocols that would return eligible deferred blood donors, in light of current scientific data, to active status. Interact with the FDA on these issues as appropriate.
 5. Monitor and report to the Board on developments of new tests to detect bacterial contamination. Serve as a resource for evolving regulatory and policy issues relating to this topic.
 6. Coordinate with the Clinical Transfusion Medicine Committee as needed and appropriate.
 7. Maintain a prioritized matrix of emerging infectious diseases offering actual or potential risk to blood or transfusion safety, to be used as a strategic tool for Committee and Association planning.
 8. Maintain EID Fact Sheets posted on the AABB web site.
 9. Monitor developments in TSE testing and removal technologies and report to the Board as appropriate.
 10. Serve as a resource for the Communications staff to develop articles and other communications for the membership on issues of interest to the membership identified by the committee.
 11. Serve as a resource for staff in the development and review of statements before BPAC, the Advisory Committee on Blood Safety and Availability, and similar groups and scientific statements to the press and public. Present statements on behalf of AABB as requested.

Current Personnel as of May 20, 2024

Name	Roles
<u>Chair</u>	
Jed Gorlin	
<u>CHIEF MEDICAL OFFICER</u>	
Dr. Claudia Cohn, MD, PHD	
<u>Consultant</u>	
Dr. Michael P. Busch, MD,PHD	
Dr Roger Dodd	
Scott Koepsell	
Susan L. Stramer, PhD	

Name	Roles
Dr. Brian Custer	
<u>Ex Officio</u>	
Dr. Laura Tonnetti, PHD	
Dr Jessica Jacobson	
Dr Louis Katz	
Prof. F. Blaine Hollinger	
Dr. Marion Lanteri	
<u>Junior Committee Member</u>	
Mei San Tang	
Dr. Tobias Cohen, MD,PHD	
<u>Liaison</u>	
Dr Mary Townsend	DHTF Liaison
Ryan Metcalf	CTMC Liaison (Chair)
<u>Member</u>	
Deanna Fang	
Dr. Cheryl Ann Lobo	
Dr Susan Galel	
Ralph Vassallo	
DR Cathy Conry-Cantilena	
Dr Suchitra Pandey	
Dr Theresa Nester	
Bethany Brown	
Dr. Aikaj Jindal, MD	
Nour Almozain, CABP	
Dr. Christian Parcher Nixon, MD, PHD	
<u>Representative</u>	
Brychan Clark, MD	FDA (OTP) Rep.
Dr. Paula Saa, MS, PHD	ARC Rep.
Dr. Hira L Nakhasi PhD	FDA (OBRR) Rep.
Mr. Jeffrey Hebert, MLS(ASCP)SBB	U.S. Military/ASBP/DoD Rep.
Mr. Jan Zajdowicz, MS	AATB Rep.
Ms. Kelley E. Garner	CSTE Rep.
Dr. Deva Sharma	ASH Rep.
Sanjai Kumar	FDA (OBRR) Rep.
Dr. Thomas R. Kreil Ph.D.	PPTA Rep.
Sheila O'Brien	CBS Rep.
Ian Kracalik	CDC Rep.



Name	Roles
Courtney Hopkins	ABC Rep.
<u>Staff Liaison</u>	
Karen Palmer	

Time Commitment: To learn about the time commitments for this committee, please contact the staff liaison listed in the roster above.